Cycle for Survival funds promise: Our donations launch and accelerate research studies and clinical trials that drive discovery. By helping fill the funding gap in rare cancer research, participants and donors are giving hope that one day, all rare cancer patients will have the treatment options they need and deserve.
Since 2007, more than $50 million has been raised for the fight.
2014 was the biggest fundraising year yet for Cycle for Survival!
100% of Cycle for Survival funds go directly to pioneering research initiatives led by
Memorial Sloan Kettering Cancer Center (MSK) within six months of the annual events.
MSK is the nation's #1 cancer care hospital, as ranked by U.S. News & World Report—and has long been the preeminent center for research devoted exclusively to cancer. MSK’s clinicians treat over 400 subtypes of cancer, and the discoveries made here benefit patients around the world. MSK has produced more FDA-approved drugs for the treatment of cancer than any other single academic institution.
that will benefit patients worldwide:
Cycle for Survival
Advanced Bladder Cancer
Chronic Lymphocytic Leukemia
Germ Cell Tumors
Metastatic Bladder Cancer
Pancreatic Ductal Adenocarcinoma
Pancreatic Neuroendocrine Tumors
Germ Cell Tumors
Cycle for Survival 2014: The biggest and most successful event season yet!
See this year's record-breaking numbers compared to 2013
Thanks to our committed and determined participants and donors, the funds raised in 2014 will advance many vital areas of research. In addition to the allocations for individual, specific rare cancer research projects, Cycle for Survival donations also support the advancement of large-scale research initiatives. Most of these efforts have a common thread: finding better ways for patients to receive medicine tailored to their specific disease. We’re proud to contribute to these innovative efforts that will change the way cancer is diagnosed and treated.
Sequencing Rare Tumors
Genome sequencing of tumors is a powerful way for doctors to deliver precision medicine—a highly personalized and highly effective approach to treating cancer based on the tumors’ exact makeup. The Diagnostic Molecular Pathology laboratory, under the leadership of Drs. Marc Ladanyi and David Klimstra, will use Cycle for Survival funding to take their methods and technology to the next level. They are creating a better way to capture, view and archive sequencing data. Their ultimate goals are to increase the number and types of tumors that can be tested and analyzed, to refine the list of genes being sequenced, and to provide well-annotated reports that convey the significance of the results.
Study of Microbes, Inflammation and Cancer
The Lucille Castori Center for Microbes, Inflammation, and Cancer was created to shed light on the role that microbes (like bacteria and viruses) and inflammatory and immune responses play in cancer. Members of the Center study microbes that are associated with cancer progression, and those that prevent infections and limit cancer growth. Cycle for Survival funds given to the Castori Center, under the leadership of Dr. Eric G. Pamer, will support microbiome sequencing. The information gathered from this effort will help researchers learn about rare tumors—informing best treatments for patients.
Phase I Clinical Trials for Rare Cancers
The Center for Mechanism-Based Therapy, under the leadership of Drs. José Baselga and Neal Rosen, is MSK’s hub for clinical trials that serve patients with rare cancers. A shift is under way in cancer treatment. In the past, medicines were evaluated in specific tumor types, often leaving patients with rare tumors few investigational options. As we understand more about molecular targets that drive the growth of tumors, newer medicines target these without regard to the tumor type. Since many rare tumors have these mutations of interest, patients with rare tumors now have more options than ever before for clinical trial participation. Cycle for Survival funding will help to increase the discovery of agents and targets as well as improve the efficiency of managing these trials—reaching far more patients battling a rare cancer.
The Marie-Josée and Henry R. Kravis Center for Molecular Oncology
The Marie-Josée and Henry R. Kravis Center for Molecular Oncology, led by Dr. David Solit, will utilize Cycle for Survival funding to advance a revolutionary approach to cancer diagnosis and treatment. “Driver” mutations promote and maintain tumors. Therapies that target these mutations can have a dramatic positive effect on patients because they attack cancer’s fundamental vulnerabilities. The Center’s new project involves an in-depth study of tumors that have no known mutation—with a focus on rare cancers. This large-scale initiative will bring new answers and more powerful treatments to patients.
The Sarcoma Medical Oncology Service, led by Dr. William Tap, will use Cycle for Survival funding to ensure that patients benefit immediately from research breakthroughs. First, the team will advance clinical trials testing immunotherapies, which help the immune system to better recognize and attack sarcoma—and targeted therapies, which disable sarcomas’ means of survival and growth. The team will also increase the breadth and depth of basic science and translational research, which bridges lab discoveries to patients’ bedsides. Finally, the Jennifer Goodman Linn Laboratory of New Drug Development in Sarcoma and Rare Cancers will expand its innovative, highly promising research agenda. All of these efforts will deliver new and better treatments to sarcoma patients.
The MSK Functional Genomics Initiative
Recent advances in technology have made it possible, for the first time, to conduct comprehensive genomic screening of patients with advanced cancer. MSK is leading this effort, with the ultimate goal of performing this testing in every patient with recurrent or metastatic disease. Cycle for Survival funding will support collaborative research projects to study the function of specific drivers (mutations, errors, etc.) in patients with rare cancers. Scientists also will seek to pinpoint the exact events that promote tumor formation and progression. The long-term aim is to leverage these discoveries into more powerful, personalized cancer treatments.
Select Projects Supported by
2014 Cycle for Survival Donations
Thirteen Cycle for Survival grant recipients were chosen, based on the merit of their proposals, to pursue unique approaches and ideas that will impact the diagnosis and treatment of rare cancer patients. Each recipient was selected by a committee comprised of their peers and MSK's leadership. It's an honor to support their work—all thanks to generous and devoted Cycle for Survival participants and donors.
The funds raised in 2014 were also allocated to specific areas of research to support new and ongoing efforts to learn more about rare cancers and how to defeat them. All of these projects embody hope and progress for patients around the world who are battling rare cancers.
Dr. Charlotte Ariyan is conducting a first-ever study combining immunotherapy and regional chemotherapy in patients with recurrent melanoma.
Drs. Sarat Chandarlapaty and Rachel Grisham are studying a genetic mutation that likely plays a crucial role in the aggressive and difficult nature of certain metastatic endometrial cancers, and they’re developing new drugs to overcome the problem.
Pancreatic Ductal Adenocarcinoma
Drs. Richard Do and Amber Simpson are testing an exciting new method of imaging pancreatic cancer heterogeneity, with the potential of improving prognostication and future targeted treatments.
Germ Cell Tumors
Dr. Darren Feldman is analyzing the cause of chemotherapy resistance in patients with germ cell tumors.
Drs. Helena Furberg Barnes and Vijai Joseph are conducting the first-ever genome-wide pharmacogenetic study to determine which patients with advanced bladder cancer will respond to chemotherapy.
Pancreatic Neuroendocrine Tumors
Dr. Xuejun Jiang is developing and testing an entirely new class of drugs to treat pancreatic neuroendocrine tumors.
Drs. Kay Park and Rajmohan Murali are studying the genetic basis of gastric-type cervical adenocarcinoma, an aggressive type of cervical cancer not caused by HPV, with the goal of improving the diagnosis and treatment of women with this tumor.
Dr. Andreas Rimner will conduct a multicenter trial to determine the efficacy of a lung sparing radiation approach developed at MSK that will be given in conjunction with surgery and chemotherapy for patients with malignant pleural mesothelioma.
Dr. Barry Taylor is leading an innovative study to pinpoint the origins of metastatic bladder cancer—laying a vital foundation for development of new therapies.
Dr. Cristina Antonescu is studying cancer-promoting signaling in angiosarcoma, using advanced sequencing techniques, among other methods. Her lab is also developing a new model of angiosarcoma—which will foster accurate, rapid testing of new therapies.
Dr. Stephen Roberts
is developing new neuroblastoma models to better understand pathways that lead to the diverse clinical behavior of this disease—with the goal of delivering more effective therapies to patients.
Drs. Andrea Cercek and Garrett Nash are advancing a clinical trial that compares two forms of intraperitoneal chemotherapy for patients with cancers of the appendix, colon, or rectum that have spread to the abdominal lining.
Dr. Daniel Coit will expand a vital, ongoing effort to dissect the genetic profile of gastric cancer, with the goal of improving the ability to estimate prognosis and predict treatment response.
Pediatric Brain Tumors
Dr. Ira Dunkel is advancing a clinical trial testing enhanced delivery of a novel medication for children with DIPG brain tumors.
Drs. Paul Meyers and Heather Magnan are leading a clinical trial to test an enhanced treatment regimen that incorporates an additional two powerful chemotherapy drugs with the five drugs previously used to treat Ewing Sarcoma.
Dr. Roisin O'Cearbhaill is advancing a clinical trial to determine if giving hyperthermic intraperitoneal chemotherapy during surgery, followed by chemotherapy, is more effective than postoperative chemotherapy alone for women undergoing a second cancer surgery.
Drs. Leonard Wexler and Cristina Antonescu are pinpointing the genetic mutations driving rhabdomyosarcoma, and creating accurate models of the disease—with the goal of testing new therapies.